High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay
Abstract SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immun...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-91300-5 |
| id |
doaj-27dfd414a1384a84aa5cb8b2992de9c1 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Markus H. Kainulainen Eric Bergeron Payel Chatterjee Asheley P. Chapman Joo Lee Asiya Chida Xiaoling Tang Rebekah E. Wharton Kristina B. Mercer Marla Petway Harley M. Jenks Timothy D. Flietstra Amy J. Schuh Panayampalli S. Satheshkumar Jasmine M. Chaitram S. Michele Owen Laura K. McMullan Mike Flint M. G. Finn Jason M. Goldstein Joel M. Montgomery Christina F. Spiropoulou |
| spellingShingle |
Markus H. Kainulainen Eric Bergeron Payel Chatterjee Asheley P. Chapman Joo Lee Asiya Chida Xiaoling Tang Rebekah E. Wharton Kristina B. Mercer Marla Petway Harley M. Jenks Timothy D. Flietstra Amy J. Schuh Panayampalli S. Satheshkumar Jasmine M. Chaitram S. Michele Owen Laura K. McMullan Mike Flint M. G. Finn Jason M. Goldstein Joel M. Montgomery Christina F. Spiropoulou High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay Scientific Reports |
| author_facet |
Markus H. Kainulainen Eric Bergeron Payel Chatterjee Asheley P. Chapman Joo Lee Asiya Chida Xiaoling Tang Rebekah E. Wharton Kristina B. Mercer Marla Petway Harley M. Jenks Timothy D. Flietstra Amy J. Schuh Panayampalli S. Satheshkumar Jasmine M. Chaitram S. Michele Owen Laura K. McMullan Mike Flint M. G. Finn Jason M. Goldstein Joel M. Montgomery Christina F. Spiropoulou |
| author_sort |
Markus H. Kainulainen |
| title |
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay |
| title_short |
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay |
| title_full |
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay |
| title_fullStr |
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay |
| title_full_unstemmed |
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay |
| title_sort |
high-throughput quantitation of sars-cov-2 antibodies in a single-dilution homogeneous assay |
| publisher |
Nature Publishing Group |
| series |
Scientific Reports |
| issn |
2045-2322 |
| publishDate |
2021-06-01 |
| description |
Abstract SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA. |
| url |
https://doi.org/10.1038/s41598-021-91300-5 |
| work_keys_str_mv |
AT markushkainulainen highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT ericbergeron highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT payelchatterjee highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT asheleypchapman highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT joolee highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT asiyachida highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT xiaolingtang highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT rebekahewharton highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT kristinabmercer highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT marlapetway highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT harleymjenks highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT timothydflietstra highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT amyjschuh highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT panayampallissatheshkumar highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT jasminemchaitram highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT smicheleowen highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT laurakmcmullan highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT mikeflint highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT mgfinn highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT jasonmgoldstein highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT joelmmontgomery highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay AT christinafspiropoulou highthroughputquantitationofsarscov2antibodiesinasingledilutionhomogeneousassay |
| _version_ |
1721379545715572736 |
| spelling |
doaj-27dfd414a1384a84aa5cb8b2992de9c12021-06-13T11:40:16ZengNature Publishing GroupScientific Reports2045-23222021-06-011111910.1038/s41598-021-91300-5High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assayMarkus H. Kainulainen0Eric Bergeron1Payel Chatterjee2Asheley P. Chapman3Joo Lee4Asiya Chida5Xiaoling Tang6Rebekah E. Wharton7Kristina B. Mercer8Marla Petway9Harley M. Jenks10Timothy D. Flietstra11Amy J. Schuh12Panayampalli S. Satheshkumar13Jasmine M. Chaitram14S. Michele Owen15Laura K. McMullan16Mike Flint17M. G. Finn18Jason M. Goldstein19Joel M. Montgomery20Christina F. Spiropoulou21Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionSchool of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of TechnologyReagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and PreventionReagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and PreventionReagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and PreventionEmergency Response Branch, Division of Laboratory Sciences, Centers for Disease Control and PreventionNewborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, Centers for Disease Control and PreventionReagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionDivision of Laboratory Systems, Centers for Disease Control and PreventionNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionSchool of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of TechnologyReagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and PreventionAbstract SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA.https://doi.org/10.1038/s41598-021-91300-5 |